History suggests β agonists, the cognate ligand of the β 2 adrenoceptor, have been used as
bronchodilators for around 5,000 years, and β agonists remain today the frontline treatment …

The β-adrenoceptor agonists (β-agonists) have been used to relieve bronchoconstriction for
at least 5000 years. β-agonists are based on adrenaline and early forms, such as …

Conclusion The introduction of long-acting inhaled β 2-agonists has been a major
therapeutic development, and has led to a fundamental reappraisal of β 2-agonist use in …

Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …

Inhaled β2-adrenoceptor agonists are by far the most effective and safe bronchodilators
currently available. They have not been surpassed by any other bronchodilating principle …

BACKGROUND Despite widespread use of adrenergic agents in the management of
asthma for many decades, doubts have emerged concerning the safety and efficacy of long …

In the last two decades several significant changes have been proposed in the receptor
theory that describes how ligands can interact with G protein‐coupled receptors (GPCRs) …

β2-Agonists are effective bronchodilators due primarily to their ability to relax airway smooth
muscle (ASM). They exert their effects via their binding to the active site of β2-adrenoceptors …

β2-adrenoceptor agonists are the first-line treatment of asthma and chronic obstructive
pulmonary disease (COPD), in which a short-acting β2-adrenoceptor agonist is used as …

The human β-adrenoceptor is a member of the seven-transmembrane family of receptors,
encoded by a gene on chromosome 5. β-Adrenoceptors have been classified into β1, β2 …